The quarterly is your only hope for news on revenue IMO.Nothing else likely or on the horizon from the signals, or lack of, that I can see.Just an opinion but 'hope springs eternal'!CheersCabe
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%